A detailed history of Northern Trust Corp transactions in Exagen Inc. stock. As of the latest transaction made, Northern Trust Corp holds 15,745 shares of XGN stock, worth $45,660. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,745
Previous 16,307 3.45%
Holding current value
$45,660
Previous $29,000 65.52%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$1.74 - $3.42 $977 - $1,922
-562 Reduced 3.45%
15,745 $48,000
Q2 2024

Aug 14, 2024

SELL
$1.36 - $2.05 $85 - $129
-63 Reduced 0.38%
16,307 $29,000
Q1 2024

May 14, 2024

SELL
$1.42 - $2.3 $99 - $161
-70 Reduced 0.43%
16,370 $26,000
Q2 2022

Aug 12, 2022

SELL
$4.18 - $7.74 $287,040 - $531,505
-68,670 Reduced 80.68%
16,440 $94,000
Q1 2022

May 13, 2022

SELL
$7.12 - $11.06 $31,634 - $49,139
-4,443 Reduced 4.96%
85,110 $684,000
Q4 2021

Feb 08, 2022

SELL
$8.97 - $14.08 $27,143 - $42,606
-3,026 Reduced 3.27%
89,553 $1.04 Million
Q3 2021

Nov 15, 2021

SELL
$10.25 - $15.21 $49,446 - $73,373
-4,824 Reduced 4.95%
92,579 $1.26 Million
Q2 2021

Aug 13, 2021

BUY
$12.4 - $17.92 $542,921 - $784,609
43,784 Added 81.66%
97,403 $1.46 Million
Q1 2021

May 12, 2021

SELL
$13.9 - $22.0 $50,359 - $79,706
-3,623 Reduced 6.33%
53,619 $938,000
Q4 2020

Feb 11, 2021

BUY
$11.19 - $16.05 $637 - $914
57 Added 0.1%
57,242 $755,000
Q3 2020

Nov 16, 2020

SELL
$10.56 - $16.69 $32,978 - $52,122
-3,123 Reduced 5.18%
57,185 $620,000
Q2 2020

Aug 14, 2020

BUY
$11.0 - $16.7 $186,472 - $283,098
16,952 Added 39.1%
60,308 $748,000
Q1 2020

May 14, 2020

BUY
$12.7 - $25.95 $81,089 - $165,690
6,385 Added 17.27%
43,356 $691,000
Q4 2019

Feb 14, 2020

BUY
$12.61 - $28.48 $466,204 - $1.05 Million
36,971 New
36,971 $939,000

Others Institutions Holding XGN

About EXAGEN INC.


  • Ticker XGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 16,260,400
  • Market Cap $47.2M
  • Description
  • Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus ery...
More about XGN
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.